Salute e Benessere
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Through this collaboration, , the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's towards and , with a lead asset for progressing rapidly.
Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as , , and .
"Securing Shilpa as our lead investor is a transformative step," said , . "Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated."
"Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market," said ,
"Shilpa has always focused on enabling breakthrough biologics," said ,
. "This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development."
The financing round remains open to other strategic investors who share Alveolus Bio's vision of transforming respiratory medicine.
Shilpa Medicare is a global pharmaceutical company with capabilities across drug discovery to commercialization, specializing in respiratory therapeutics and biotech innovation. Visit www.vbshilpa.com.
A Biostack Ventures company, Alveolus Bio is developing first-in-class therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs for COPD, BPD, Pulmonary Fibrosis, Cystic Fibrosis, and more.
Logo: https://mma.prnewswire.com/media/2489785/4876931/Shilpa_Logo.jpg
Logo: https://mma.prnewswire.com/media/2741744/Alveolus_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-groundbreaking-pulmonary-therapeutics-302519451.html